Department of Radiation Oncology, University of Toronto, Toronto.
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto.
Curr Oncol. 2020 Aug;27(4):179-189. doi: 10.3747/co.27.5959. Epub 2020 Aug 1.
Radiation-induced chest wall pain (cwp) and rib fracture (rf) are late adverse effects after stereotactic body radiation therapy (sbrt) for stage i non-small-cell lung cancer (nsclc); however, the literature about their incidence and risk factors shows variability. We performed a systematic review to determine the pooled incidence of cwp and rf in the relevant population.
A literature search using the prisma (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines considered English publications in medline and embase from January 1996 to August 2017. Abstracts were screened, followed by full-text review and data extraction.
The database searches identified 547 records. Twenty-eight publications comprising 3892 patients met the inclusion criteria. Median reported ages and follow-up durations fell into the ranges 67-82 years and 12-84 months. Prescriptions fell into the range of 40-70 Gy in 3-10 fractions. Despite study heterogeneity, the pooled incidences of cwp and rf were estimated to be 8.94% and 5.27% respectively. Nineteen studies reported cwp grade: 58 of 308 patients (18.8%) experienced grades 3-4 cwp (no grade 5 events reported). Thirteen studies reported rf grade: grades 3-4 rf were observed in 9 of 113 patients (7.96%). A high chest wall was an important predictor of cwp and rf.
In patients with stage i nsclc, rates of cwp and rf after sbrt are low; however, tumour location, accurate toxicity reporting, and dose-fractionation schemes might alter those rates. Prospective correlation with dosimetry and quality of life assessment will further improve the understanding of cwp and rf after sbrt.
立体定向体部放射治疗(SBRT)治疗 I 期非小细胞肺癌(NSCLC)后,会出现放射性胸壁疼痛(CWP)和肋骨骨折(RF)等晚期不良反应;然而,关于其发生率和危险因素的文献存在差异。我们进行了一项系统评价,以确定相关人群中 CWP 和 RF 的合并发生率。
使用 PRISMA(系统评价和荟萃分析的首选报告项目)指南进行文献检索,考虑了 1996 年 1 月至 2017 年 8 月期间 MEDLINE 和 Embase 中的英文出版物。筛选摘要,然后进行全文审查和数据提取。
数据库搜索共确定了 547 条记录。28 篇出版物包含 3892 名患者,符合纳入标准。报告的中位年龄和随访时间分别为 67-82 岁和 12-84 个月。处方剂量范围为 3-10 次分割,40-70 Gy。尽管存在研究异质性,但 CWP 和 RF 的合并发生率估计分别为 8.94%和 5.27%。19 项研究报告了 CWP 分级:308 名患者中有 58 名(18.8%)出现 3-4 级 CWP(无 5 级事件报告)。13 项研究报告了 RF 分级:113 名患者中有 9 名(7.96%)出现 3-4 级 RF。高胸壁是 CWP 和 RF 的重要预测因子。
在 I 期 NSCLC 患者中,SBRT 后 CWP 和 RF 的发生率较低;然而,肿瘤位置、准确的毒性报告和剂量分割方案可能会改变这些发生率。与剂量学和生活质量评估的前瞻性相关性将进一步提高对 SBRT 后 CWP 和 RF 的认识。